Back to top
more

BioTechne Corp (TECH)

(Delayed Data from NSDQ)

$62.73 USD

62.73
902,986

-1.28 (-2.00%)

Updated Apr 17, 2024 04:00 PM ET

After-Market: $62.70 -0.03 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for TECH

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for BioTechne Corp falls in the month of June.

All items in Millions except Per Share data.

6/30/2023 6/30/2022 6/30/2021 6/30/2020 6/30/2019
Assets          
Cash & Equivalents 204 247 232 271 166
Receivables 218 195 145 123 137
Notes Receivable 0 0 0 0 0
Inventories 172 141 117 103 91
Other Current Assets 27 23 17 24 18
Total Current Assets 621 606 511 521 413
Net Property & Equipment 226 223 208 177 154
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 1,407 1,354 1,459 1,245 1,312
Deposits & Other Assets 285 47 12 14 6
Total Assets 2,639 2,295 2,263 2,028 1,884
Liabilities & Shareholders Equity 6/30/2023 6/30/2022 6/30/2021 6/30/2020 6/30/2019
Notes Payable 0 0 0 0 0
Accounts Payable 26 34 29 23 16
Current Portion Long-Term Debt 0 13 13 13 13
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 52 80 67 40 55
Income Taxes Payable 12 13 5 2 6
Other Current Liabilities 28 25 27 19 12
Total Current Liabilities 129 176 152 107 102
Mortgages 0 0 0 0 0
Deferred Taxes/Income 89 99 93 101 90
Convertible Debt 0 0 0 0 0
Long-Term Debt 350 243 329 344 493
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 11 17 50 27 34
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 672 594 692 646 719
Shareholders Equity 6/30/2023 6/30/2022 6/30/2021 6/30/2020 6/30/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 2 0 0 0 0
Capital Surplus 722 654 534 421 317
Retained Earnings 1,309 1,123 1,085 1,057 932
Other Equity -66 -76 -49 -97 -84
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 1,967 1,701 1,571 1,381 1,166
Total Liabilities & Shareholder's Equity 2,639 2,295 2,263 2,028 1,884
Total Common Equity 1,967 1,701 1,571 1,381 1,166
Shares Outstanding 157.40 156.90 155.50 152.80 151.40
Book Value Per Share 12.49 10.84 10.10 9.04 7.70

Fiscal Year End for BioTechne Corp falls in the month of June.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 136 149 204 157
Receivables NA 207 205 218 216
Notes Receivable NA 0 0 0 0
Inventories NA 181 186 172 169
Other Current Assets NA 67 52 27 28
Total Current Assets NA 591 591 621 571
Net Property & Equipment NA 234 232 226 224
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 1,531 1,548 1,407 1,424
Deposits & Other Assets NA 274 282 285 283
Total Assets NA 2,731 2,755 2,639 2,600
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 32 28 26 27
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 50 51 52 54
Income Taxes Payable NA 7 6 12 18
Other Current Liabilities NA 34 31 28 31
Total Current Liabilities NA 135 128 129 141
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 72 83 89 95
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 447 440 350 370
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 9 11 11
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 767 758 672 710
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 2 2 2 2
Capital Surplus NA 764 747 722 715
Retained Earnings NA 1,261 1,328 1,309 1,247
Other Equity NA -64 -78 -66 -74
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 1,964 1,998 1,967 1,890
Total Liabilities & Shareholder's Equity NA 2,731 2,755 2,639 2,600
Total Common Equity 0 1,964 1,998 1,967 1,890
Shares Outstanding 157.10 158.10 158.20 157.40 157.20
Book Value Per Share 0.00 12.42 12.63 12.49 12.02